Back to results
US 2024/0358708 A1Published application
Methods and pharmaceutical compositions for treating lymphoid malignancy
AssigneeThomas DIACOVO
InventorThomas DIACOVO
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeThomas DIACOVO
InventorThomas DIACOVO
Estimating the term…
The present invention provides, inter alia, methods for treating, preventing, or ameliorating the effects of a lymphoid malignancy, such as those associated with a mutated phosphatase and tensin homolog (PTEN) gene, or T-cell acute lymphoblastic leukemia (T-ALL). These methods include administering to a subject an effective amount of a phosphoinositide 3-kinase-delta (PI3Kδ) inhibitor and a phosphoinositide 3-kinase-gamma (PI3Kγ) inhibitor. The present invention also provides pharmaceutical compositions for treating the effects of a lymphoid malignancy. This invention further provides a method for identifying a subject who may benefit from co-treatment with a PI3Kδ inhibitor and a PI3Kγ inhibitor. This method includes determining from a sample of the subject whether the subject has a mutated PTEN gene. Additionally, this invention provides methods for identifying a compound that has both PI3Kδ and PI3Kγ inhibitory activity.
-20. (canceled)
A method for treating or ameliorating the effects of a lymphoid malignancy in a subject comprising administering to a subject in need thereof an effective amount of a compound that selectively inhibits both phosphoinositide 3-kinase-delta (PI3Kδ) and phosphoinositide 3-kinase-gamma (PI3Kγ) and wherein the lymphoid malignancy is T-cell acute lymphoblastic leukemia (T-ALL) or T-cell acute lymphoblastic lymphoma.
A method for treating or ameliorating the effects of a lymphoid malignancy associated with a mutated phosphatase and tensin homolog (PTEN) gene in a subject comprising administering to the subject an effective amount of a compound that selectively inhibits both phosphoinositide 3-kinase-delta (PI3Kδ) and phosphoinositide 3-kinase-gamma (PI3Kγ).
A method for treating or ameliorating the effects of a lymphoid malignancy in a subject comprising administering to a subject in need thereof a co-treatment effective amount of a combination of an inhibitor of phosphoinositide 3-kinase-delta (PI3Kδ) and an inhibitor of phosphoinositide 3-kinase-gamma (PI3Kγ), said treatment comprising co-administration of each inhibitor or administrating each inhibitor sequentially being sufficiently spaced apart to achieve a clinically effective result, wherein the lymphoid malignancy is T-cell acute lymphoblastic leukemia (T-ALL) or T-cell acute lymphoblastic lymphoma.
Dependencies are inferred from the claim text.